Overview

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

Phase:

Phase 1

Details

Lead Sponsor:

Robert Negrin

Collaborator:

National Institutes of Health (NIH)